The People's Perspective on Medicine

Is New Cancer Drug Worth the Price?

Will the new cancer drug Xpovio work well enough to justify its extremely high price tag? Oncologists are also worried about dangerous side effects.

The FDA has just approved a new cancer drug to treat multiple myeloma. This blood cancer affects the white blood cells that would normally make antibodies. Although there are treatments for multiple myeloma, many lose their effectiveness over time. Strictly speaking, the FDA approved this new cancer drug only for a select group of patients. The agency specified hose whose multiple myeloma is progressing despite having tried at least five other treatments.

What Will This Medication Cost?

The new cancer drug is selinexor. It will carry the brand name Xpovio and is expected to cost $22,000 a month. Scientists affiliated with the manufacturer included 83 people in the trial. In the study, they paired selinexor with the powerful steroid drug dexamethasone. This may be used alone or in combination with other medications to treat multiple myeloma. According to study results, selinexor reduced signs of multiple myeloma about one-fourth of the time. However, this study design is far from ideal for scientists to determine efficacy.

Side Effects of the New Cancer Drug Xpovio:

This cancer treatment is controversial. Before the FDA approved it as a last-ditch therapy, an outside panel of experts voted against approval. Some experts believe that approval was premature. These are primarily cancer specialists serving on the FDA’s Oncologic Drugs Advisory Committee.

According to the committee briefing document, roughly 90 percent of patients had at least one serious or life-threatening side effect from the therapy. These included significant drops in white blood cells, red blood cells, platelets and neutrophils. Sodium levels may also plummet. Patients complained of serious fatigue, fever, nausea, vomiting, diarrhea or constipation and loss of appetite.

Rate this article
5- 3 ratings
About the Author
Terry Graedon, PhD, is a medical anthropologist and co-host of The People’s Pharmacy radio show, co-author of The People’s Pharmacy syndicated newspaper columns and numerous books, and co-founder of The People’s Pharmacy website. Terry taught in the Duke University School of Nursing and was an adjunct assistant professor in the Department of Anthropology. She is a Fellow of the Society of Applied Anthropology. Terry is one of the country's leading authorities on the science behind folk remedies. .
Tired of the ads on our website?

Now you can browse our website completely ad-free for just $5 / month. Stay up to date on breaking health news and support our work without the distraction of advertisements.

Browse our website ad-free
Join over 150,000 Subscribers at The People's Pharmacy

We're empowering you to make wise decisions about your own health, by providing you with essential health information about both medical and alternative treatment options.

Showing 4 comments
Add your comment

The FDA isn’t doing it’s job once again, and $22,000 a month to live, perhaps not well with, and with terrible potential side effects is unethical and immoral. Pharma’s goal is to become wealthier, not to help people, as most cannot afford the tariff of new designer drugs.

The FDA/BigPharma/MainstreamMedical: Money, money, ready or not here we come – yet ANOTHER new thing to try. To heck with anything that may help if it’s not profitable. All you out there, check out the site: The Truth About Cancer – if you delve into it you may get a bit upset trying to figure out how so many ‘things’ have been withheld that can even thwart cancer…but then, they’re not profitable….

Shame on pharmaceutical companies. $22,000.00 A month for a cancer drug pill. I would be ashamed to even say it.

Compare this cost with the fact that Jonas Salk refused to patent the Polio Vaccine, since he felt it was such a vital social need!

* Be nice, and don't over share. View comment policy^